Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives a detailed overview of treatment approaches for patients with relapsed/refractory (R/R) multiple myeloma from a European perspective. Dr Cerchione first discusses the importance of monoclonal antibodies (mAbs), including rituximab and daratumumab, and further highlights combination approaches being explored with these agents. Dr Cerchione then explains the growing role of bispecific antibodies in this space and highlights clinical trials investigating these agents, and concludes by commenting on the promise of CAR-T cell therapy. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.